- Home
- PEGA vs KRYS Comparison
PEGA vs KRYS Comparison
Compare PEGA & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PEGA | KRYS |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 7.8B |
| IPO Year | 1996 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PEGA | KRYS |
|---|---|---|
| Price | $36.14 | $261.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 11 |
| Target Price | $60.13 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 2.5M | 205.9K |
| Earning Date | 04-21-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | 91.89 | ★ 128.00 |
| EPS | 0.18 | ★ 6.84 |
| Revenue | ★ $682,695,000.00 | $389,130,000.00 |
| Revenue This Year | $15.99 | $38.74 |
| Revenue Next Year | $11.90 | $32.53 |
| P/E Ratio | $197.56 | ★ $38.08 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $34.34 | $123.03 |
| 52 Week High | $105.50 | $298.30 |
Technical Indicators
Market Signals| Indicator | PEGA | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 36.40 | 46.21 |
| Support Level | $35.11 | $254.53 |
| Resistance Level | $44.95 | $263.75 |
| Average True Range (ATR) | 2.20 | 9.24 |
| MACD | -0.47 | -1.02 |
| Stochastic Oscillator | 17.45 | 17.88 |
Price Performance
Historical ComparisonAbout PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.